Screener / SEC EDGAR /CIK 0001991792 /10-K filed Feb 27, 2026, compared with Mar 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

CG Oncology, Inc. CGON

Compare with peers Embed

CGON among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+255%3rd of 155 · median +10.5%
Return on equity
-5.2%18.5%
-24.0%120th of 144 · median 9.2%
Debt / equity (less is better)
1.160.42
0.001st of 108 · median 0.69

CGON and 9 peers, year by year

The 9 Health care companies closest to CGON in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthOperating marginNet marginFCF marginReturn on equityDebt / equity
CGON CG Oncology, Inc. FY2025 $4.0M+255%n/mn/mn/m−21.4%0.00
SRRK Scholar Rock Holding Corp FY2025 $0----−154.0%0.41
CRSP CRISPR Therapeutics AG FY2025 $3.5M−90.6%n/mn/mn/m−30.3%0.00
IDYA IDEAYA Biosciences, Inc. FY2025 $218.7Mn/m−72.8%−52.0%−33.6%−11.1%-
ROIV Roivant Sciences Ltd. FY2026 $8.3M−71.6%n/mn/mn/m−6.6%-
OCUL Ocular Therapeutix, Inc FY2025 $52.0M−18.5%−519.8%−511.9%−417.5%−40.6%0.11
RXRX Recursion Pharmaceuticals, Inc. FY2025 $74.7M+26.9%−867.9%−863.4%−506.5%−57.0%0.02
KYMR Kymera Therapeutics, Inc. FY2025 $39.2M−16.7%−891.1%−794.0%−597.6%−19.7%-
CYTK Cytokinetics Inc FY2025 $88.0M+377%−695.4%−891.6%−607.5%n/mn/m
AGIO Agios Pharmaceuticals, Inc. FY2025 $54.0M+48.0%−873.9%−764.0%−698.3%−34.6%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2023 to FY2025 · 10-K XBRL

CGONCG Oncology, Inc.
FY2023 revenue $204KFY2024 revenue $1.1MFY2025 revenue $4.0M FY2023FY2025
Revenue$4.0M Growth+255% Net margin-
CRSPCRISPR Therapeutics AG
FY2023 revenue $371.2MFY2024 revenue $37.3MFY2025 revenue $3.5M FY2023 net margin −41.4%FY2024 net margin −981.5% FY2023FY2025
Revenue$3.5M Growth−90.6% Net margin−981.5%
IDYAIDEAYA Biosciences, Inc.
FY2023 revenue $23.4MFY2024 revenue $7.0MFY2025 revenue $218.7M FY2023 net margin −483.0%FY2025 net margin −52.0% FY2023FY2025
Revenue$218.7M Growth−70.1% Net margin−52.0%
ROIVRoivant Sciences Ltd.
FY2023 revenue $31.5MFY2024 revenue $32.7MFY2025 revenue $29.1M FY2025 net margin −592.0% FY2023FY2025
Revenue$29.1M Growth−11.2% Net margin−592.0%
OCULOcular Therapeutix, Inc
FY2023 revenue $58.4MFY2024 revenue $63.7MFY2025 revenue $52.0M FY2023 net margin −138.1%FY2024 net margin −303.7%FY2025 net margin −511.9% FY2023FY2025
Revenue$52.0M Growth−18.5% Net margin−511.9%
RXRXRecursion Pharmaceuticals, Inc.
FY2023 revenue $44.6MFY2024 revenue $58.8MFY2025 revenue $74.7M FY2023 net margin −736.0%FY2024 net margin −788.0%FY2025 net margin −863.4% FY2023FY2025
Revenue$74.7M Growth+26.9% Net margin−863.4%
KYMRKymera Therapeutics, Inc.
FY2023 revenue $78.6MFY2024 revenue $47.1MFY2025 revenue $39.2M FY2023 net margin −187.0%FY2024 net margin −475.6%FY2025 net margin −794.0% FY2023FY2025
Revenue$39.2M Growth−16.7% Net margin−794.0%
CYTKCytokinetics Inc
FY2023 revenue $7.5MFY2024 revenue $18.5MFY2025 revenue $88.0M FY2025 net margin −891.6% FY2023FY2025
Revenue$88.0M Growth+377% Net margin−891.6%
AGIOAgios Pharmaceuticals, Inc.
FY2023 revenue $26.8MFY2024 revenue $36.5MFY2025 revenue $54.0M FY2025 net margin −764.0% FY2023FY2025
Revenue$54.0M Growth+48.0% Net margin−764.0%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2023 to FY2025

Revenue as reported in the 10-K.

$0 $371.2M FY2023FY2024FY2025 SRRK: -, -, $0 SRRK CRSP: $371.2M, $37.3M, $3.5M CRSP IDYA: $23.4M, $7.0M, $218.7M IDYA ROIV: $31.5M, $32.7M, $29.1M ROIV OCUL: $58.4M, $63.7M, $52.0M OCUL RXRX: $44.6M, $58.8M, $74.7M RXRX KYMR: $78.6M, $47.1M, $39.2M KYMR CYTK: $7.5M, $18.5M, $88.0M CYTK AGIO: $26.8M, $36.5M, $54.0M AGIO CGON: $204K, $1.1M, $4.0M CGON
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $371.2M. A gap is a year with no number. A ring marks where a line starts: SRRK has no earlier 10-K here. ROIV: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2023 to FY2025

Revenue against the fiscal year before.

−92.0% +458% FY2023FY2024FY2025 CRSP: n/m, −89.9%, −90.6% CRSP IDYA: −54.1%, −70.1%, n/m IDYA ROIV: +10.8%, +3.8%, −11.2% ROIV OCUL: +13.5%, +9.0%, −18.5% OCUL RXRX: +11.9%, +32.0%, +26.9% RXRX KYMR: +67.8%, −40.1%, −16.7% KYMR CYTK: −92.0%, +145%, +377% CYTK AGIO: +88.4%, +36.1%, +48.0% AGIO CGON: -, +458%, +255% CGON
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −92.0% to +458%. A gap is a year with no number. A ring marks where a line starts: CGON, CRSP have no earlier 10-K here.

Operating margin, FY2023 to FY2025

Operating income / revenue.

−891.1% −60.0% FY2023FY2024FY2025 CRSP: −60.0%, n/m, n/m CRSP IDYA: −574.9%, n/m, −72.8% IDYA OCUL: −141.0%, −269.6%, −519.8% OCUL RXRX: −785.3%, −814.1%, −867.9% RXRX KYMR: −210.6%, −555.8%, −891.1% KYMR CYTK: n/m, n/m, −695.4% CYTK AGIO: n/m, n/m, −873.9% AGIO
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −891.1% to −60.0%. A gap is a year with no number. A ring marks where a line starts: CYTK, AGIO have no earlier 10-K here.

Net margin, FY2023 to FY2025

Net income / revenue.

−981.5% −41.4% FY2023FY2024FY2025 CRSP: −41.4%, −981.5%, n/m CRSP IDYA: −483.0%, n/m, −52.0% IDYA ROIV: n/m, n/m, −592.0% ROIV OCUL: −138.1%, −303.7%, −511.9% OCUL RXRX: −736.0%, −788.0%, −863.4% RXRX KYMR: −187.0%, −475.6%, −794.0% KYMR CYTK: n/m, n/m, −891.6% CYTK AGIO: n/m, n/m, −764.0% AGIO
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −981.5% to −41.4%. A gap is a year with no number. A ring marks where a line starts: ROIV, CYTK, AGIO have no earlier 10-K here.

Free cash flow, FY2023 to FY2025

Cash from operations minus capital spending.

−$856.1M −$73.5M FY2023FY2024FY2025 SRRK: −$145.3M, −$201.0M, −$300.6M SRRK CRSP: −$269.8M, −$144.7M, −$345.9M CRSP IDYA: −$117.6M, −$251.4M, −$73.5M IDYA ROIV: −$856.1M, −$766.6M, −$844.0M ROIV OCUL: −$76.3M, −$136.0M, −$216.9M OCUL RXRX: −$299.7M, −$372.9M, −$378.3M RXRX KYMR: −$137.3M, −$207.3M, −$234.3M KYMR CYTK: −$415.7M, −$399.8M, −$534.8M CYTK AGIO: −$297.1M, −$391.5M, −$377.3M AGIO CGON: -, −$78.9M, −$132.5M CGON
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$856.1M to −$73.5M. A gap is a year with no number. A ring marks where a line starts: CGON has no earlier 10-K here.

FCF margin, FY2023 to FY2025

Free cash flow / revenue.

−698.3% −33.6% FY2023FY2024FY2025 CRSP: −72.7%, −387.7%, n/m CRSP IDYA: −502.9%, n/m, −33.6% IDYA OCUL: −130.6%, −213.4%, −417.5% OCUL RXRX: −672.4%, −633.7%, −506.5% RXRX KYMR: −174.7%, −440.5%, −597.6% KYMR CYTK: n/m, n/m, −607.5% CYTK AGIO: n/m, n/m, −698.3% AGIO
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −698.3% to −33.6%. A gap is a year with no number. A ring marks where a line starts: CYTK, AGIO have no earlier 10-K here.

Return on equity, FY2023 to FY2025

Net income / shareholders' equity at the year end.

−154.0% 72.9% FY2023FY2024FY2025 SRRK: −73.6%, −66.8%, −154.0% SRRK CRSP: −8.2%, −19.0%, −30.3% CRSP IDYA: −18.2%, −25.9%, −11.1% IDYA ROIV: −87.2%, 72.9%, −3.7% ROIV OCUL: −88.6%, −61.4%, −40.6% OCUL RXRX: −70.8%, −44.8%, −57.0% RXRX KYMR: −37.2%, −26.8%, −19.7% KYMR AGIO: −43.4%, 43.7%, −34.6% AGIO CGON: n/m, −12.0%, −21.4% CGON
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −154.0% to 72.9%. A gap is a year with no number. A ring marks where a line starts: CGON has no earlier 10-K here.

Debt / equity, FY2023 to FY2025

Total debt / shareholders' equity at the year end.

0.00 0.72 FY2023FY2024FY2025 SRRK: 0.23, 0.14, 0.41 SRRK CRSP: -, -, 0.00 CRSP ROIV: 0.32, 0.07, - ROIV OCUL: 0.72, 0.22, 0.11 OCUL RXRX: 0.00, 0.03, 0.02 RXRX CGON: -, 0.00, 0.00 CGON
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 0.72. A gap is a year with no number. A ring marks where a line starts: CGON, CRSP have no earlier 10-K here.
CompanyFY2023FY2024FY2025
CGON Dec -0.000.00
SRRK Dec 0.230.140.41
CRSP Dec --0.00
IDYA Dec ---
ROIV Mar 0.320.07-
OCUL Dec 0.720.220.11
RXRX Dec 0.000.030.02
KYMR Dec ---
CYTK Dec n/mn/mn/m
AGIO Dec ---
Peer median0.280.100.06

EPS (diluted), FY2023 to FY2025

Diluted earnings per share, on today's share count after splits.

−$15.65 $11.64 FY2023FY2024FY2025 SRRK: −$1.99, −$2.47, −$3.29 SRRK CRSP: −$1.94, −$4.34, −$6.47 CRSP IDYA: −$1.96, −$3.36, −$1.28 IDYA ROIV: −$1.42, $5.23, −$0.24 ROIV OCUL: −$1.02, −$1.22, −$1.42 OCUL RXRX: −$1.58, −$1.69, −$1.44 RXRX KYMR: −$2.52, −$2.98, −$3.69 KYMR CYTK: −$5.45, −$5.26, −$6.54 CYTK AGIO: −$6.33, $11.64, −$7.12 AGIO CGON: −$15.65, −$1.41, −$2.08 CGON
CGON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$15.65 to $11.64. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out CGON and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: CGON's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.